Top Navigation

Shorter Influenza A Duration with Lianhuaqingwen

In this meta-analysis, the authors review the results of studies on the efficacy of lianhuaqingwen capsule (LHQW-C) compared with oseltamivir in treating influenza A virus infection. As this virus shows, the threat of pandemic influenza has remained a major, international public health concern.2 Rapid antigenic evolution in an influenza virus increases the likelihood of emergence of novel strains. Under the circumstances, if vaccines are not yet available, treatment plays a crucial role in control of the disease. By Pan Zhao MD et al, published in Alternative Therapies, Vol. 20, No. 2.

Oseltamivir, a neuraminidase inhibitor, has been widely used against influenza virus infection in the world, and it has exhibited potent efficacy in antiviral therapy. However, a major shortcoming of oseltamivir is the emergence of viral resistance. Therefore, it is of crucial importance to find an effective and safe alternative for treating influenza infection, especially in rural areas of China where the supply of oseltamivir is often insufficient. Lianhuaqingwen capsule (LHQW-C) is a traditional Chinese prescription that may be used as an alternative. This study is a meta-analysis comparing symptom duration with oseltamivir.

To gain access to this article and the rest of our extensive database of full-text articles, please register below or log in here.

Existing Users Log In
 Remember Me  
New User Registration
*Required field

,

Powered by Quadshot